Navican is hoping to bring some of the genomic testing and related services Intermountain has been offering for three years to the broader cancer community.
Through Navican, patients at Intermountain can get tested on an internally developed NGS platform that gauges a range of actionable genes implicated in cancer.
The agreement with Taiwan's Prisma Biotech is the second distribution deal in Asia for Intermountain Precision Genomics' ICG100 tumor sequencing test.
Non-randomized studies have downsides, but researchers say they are a way to gather incremental evidence on precision oncology approaches without denying patients access.
The test, called ICG100, is based on a set of 100 genes that are analyzed for mutations that can help guide a cancer patient's treatment regimen.
Co-discoverers of the link between the gene EIF2AK4 and specific types of pulmonary hypertension, Intermountain and ARUP are now collaborating to offer clinical testing.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The consortium aims to share aggregated data between its members, enabling more cancer patients to benefit from high volume-based analytics.
The partners have previously both committed to pushing President Obama's Precision Medicine Initiative forward.
Lopansri, a clinical microbiology lab medical director who makes decisions about new tests to bring on, discussed the vagaries and thorny issues with syndromic panels.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.